natgillin/translations-raw huggingface dataset:
Corbilta is not recommended to be used for treatment of extrapyramidal symptoms (e.g. involuntary movements, shaking, muscle rigidity and muscle contractions) caused by other medicines. 
Corbilta se ne preporučuje koristiti za liječenje ekstrapiramidnih simptoma (npr. nevoljnih pokreta, tresenja, mišićne ukočenosti i mišićnih kontrakcija) uzrokovanih drugim lijekovima.
5 How to store Corbilta Contents of the pack and other information 
Kako čuvati Corbiltu Sadržaj pakiranja i druge informacije
- Corbilta may induce orthostatic hypotension. 
- Corbilta može izazvati ortostatsku hipotenziju.
- Corbilta contains sucrose, and therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. 
- Corbilta sadržava saharozu te stoga bolesnici s rijetkim nasljednim problemima nepodnošenja fruktoze, malapsorpcije glukoze-galaktoze ili nedostatka saharaza-izomaltaze ne bi smjeli uzimati ovaj lijek.
Due to entacapone's affinity to cytochrome P450 2C9 in vitro (see section 5.2), Corbilta may potentially interfere with active substances whose metabolism is dependent on this isoenzyme, such as S-warfarin. 
Zbog afiniteta entakapona prema citokromu P450 2C9 in vitro (vidjeti dio 5.2), Corbilta može potencijalno interferirati s djelatnim tvarima čiji metabolizam ovisi o ovom izoenzimu, kao što je Svarfarin.
For some patients, Corbilta may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts). 
U nekih bolesnika se Corbilta možda neće dobro apsorbirati ako se uzme tijekom ili kratko nakon obroka bogatog bjelančevinama (npr. meso, riba, mliječni proizvodi, sjemenke i orašasti plodovi).
- If general anaesthesia is required, therapy with Corbilta may be continued for as long as the patient is permitted to take fluids and medicinal products by mouth. 
- Ako je potrebna opća anestezija, terapija Corbiltom može se nastaviti tako dugo dok bolesnik smije uzimati tekućinu i lijekove na usta.
In such patients it is advisable to introduce entacapone treatment as a separate treatment (entacapone tablets) and adjust the levodopa dose if necessary, before switching to Corbilta. 
Kod takvih bolesnika je preporučljivo uvesti entakapon kao odvojeni lijek (entakapon tablete) i po potrebi prilagoditi dozu levodope, prije prelaska na Corbiltu.
Serious hepatitis with mainly cholestatic features, rhabdomyolysis and neuroleptic malignant syndrome may occur with Corbilta although no cases have been identified from the clinical trial data. 
Ozbiljni hepatitis s uglavnom kolestatskim obilježjima, rabdomioliza i neuroleptički maligni sindrom mogu se javiti uz Corbiltu, iako takvi slučajevi nisu bili otkriveni u podacima iz kliničkih ispitivanja.
If other levodopa products are used concomitantly with a Corbilta tablet, the maximum dose recommendations should be followed. 
Ako se istodobno s Corbilta tabletom koriste drugi preparati levodope, moraju se pratiti preporuke o maksimalnoj dozi.
Not known (cannot be estimated from the available data) Craving for large doses of Corbilta in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome. 
Nepoznato (ne može se procijeniti na temelju dostupnih podataka) Žudnja za velikim dozama lijeka Corbilta, koje su veće od onih potrebnih za kontrolu motoričkih simptoma, što je poznato kao sindrom poremećene regulacije dopamina.
In the first study, entacapone increased the mean daily ON time by 1 h 20 min (CI 95% 45 min, 1 h 56 min) from baseline. 
U prvom ispitivanju entakapon je povisio srednje trajanje "ON" faze za 1 h 20 min (CI95% 45 min, 1 h 56 min) u odnosu na početnu vrijednost.
The most frequently reported adverse reactions with Corbilta are dyskinesias occurring in approximately 19% of patients; gastrointestinal symptoms including nausea and diarrhoea occurring in approximately 15% and 12% of patients, respectively; muscle, musculoskeletal and connective tissue pain occurring in approximately 12% of patients; and harmless reddish-brown discolouration of urine (chromaturia) occurring in approximately 10% of patients. 
Najčešće prijavljivane nuspojave Corbilte su diskinezije koje se javljaju u otprilike 19% bolesnika; gastrointestinalni simptomi uključujući mučninu i proljev javljaju se u otprilike 15%, odnosno 12% bolesnika; bol u mišićima, mišićnokoštana bol i bol vezivnog tkiva javlja se u otprilike 12% bolesnika; te bezopasna crvenkasto-smeđa diskoloracija mokraće (kromaturija) javlja se u otprilike 10% bolesnika.
Other forms of interactions: Since levodopa competes with certain amino acids, the absorption of Corbilta may be impaired in some patients on high protein diet. 
Ostali oblici interakcija: budući da se levodopa natječe s određenim aminokiselinama, apsorpcija Corbilte može biti narušena u nekih bolesnika na dijeti bogatoj bjelančevinama.
If you stop taking Corbilta 
Ako prestanete uzimati Corbiltu
Patients being treated with Corbilta and presenting with somnolence and/or sudden sleep onset episodes must be instructed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes have resolved (see section 4.4). 
Bolesnike, koji su liječeni Corbiltom i u kojih se javlja somnolencija i/ili imaju epizode iznenadnog nastupa sna, mora se uputiti da se suzdrže od upravljanja vozilima ili od aktivnosti u kojima zbog poremećene budnosti oni ili druge osobe mogu biti pod rizikom od ozbiljne ozljede ili smrti (npr. rad sa strojevima), sve dok takve ponavljajuće epizode ne prestanu (vidjeti dio 4.4).
If you forget to take Corbilta 
Ako ste zaboravili uzeti Corbiltu
Elderly: No dose adjustment of Corbilta is required for elderly. 
Starije osobe: starijim osobama nije potrebno prilagođavati dozu Corbilte.
Because the effects of Corbilta tablets are equivalent with entacapone 200 mg tablet administered concomitantly with the commercially available standard release carbidopa/levodopa preparations in corresponding doses these results are applicable to describe the effects of Corbilta as well. 
Budući da su učinci Corbilta tableta ekvivalentni s entakapon 200 mg tabletom primijenjenom istodobno s komercijalno dostupnim preparatima karbidope/levodope sa standardnim oslobađanjem u odgovarajućim dozama, ovi su rezultati isto tako primjenjivi za opis učinaka Corbilte.
When considered necessary, the replacement of Corbilta with levodopa and DDC inhibitor without entacapone or other dopaminergic treatment should proceed slowly and an increase in levodopa dose may be necessary. 
Kada se pokaže potrebnim, nadomještanje Corbilte levodopom i DDC-inhibitorom bez entakapona ili drugim dopaminergičkim liječenjem treba se odvijati polako te može biti potrebno povećanje doziranja levodope.
Management of acute overdose with Corbilta therapy is similar to acute overdose with levodopa. 
Zbrinjavanje akutnog predoziranja tijekom terapije Corbiltom slično je kao u slučaju akutnog predoziranja levodopom.
Discontinuation of Corbilta therapy: If Corbilta treatment (levodopa/carbidopa/entacapone) is discontinued and the patient is transferred to levodopa/DDC inhibitor therapy without entacapone, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms. 
Prekid liječenja Corbiltom: ako se liječenje Corbiltom (levodopa/karbidopa/entakapon) prekida i bolesnici prelaze na terapiju levodopom/DDC-inhibitorom bez entakapona, potrebno je prilagoditi doziranje drugog antiparkinsonika, osobito levodope, da bi se postigla dovoljna razina kontrole simptoma pakinsonizma.
Women should not breast-feed during treatment with Corbilta. 
Žene ne smiju dojiti tijekom liječenja Corbiltom.
The evidence of the therapeutic effects of Corbilta is based on two phase III double-blind studies, in which 376 Parkinson's disease patients with end-of-dose motor fluctuations received either entacapone or placebo with each levodopa/DDC inhibitor dose. 
Dokaz o terapijskim učincima Corbilte temelji se na dva dvostruko slijepa klinička ispitivanja faze III, u kojima je 376 bolesnika s Parkinsonovom bolešću i motoričkim fluktuacijama na kraju intervala doziranja, uz svaku dozu levodope/DDC-inhibitora primalo ili entakapon ili placebo.
c. When initiating Corbilta in patients currently treated with entacapone and levodopa/benserazide in a standard release formulation, the dosing of levodopa/benserazide should be discontinued in the previous night, and Corbilta should be started in the next morning. 
Kada se Corbilta uvodi bolesnicima koji su trenutno liječeni entakaponom i formulacijom sa standardnim oslobađanjem levodope/benzerazida, potrebno je prekinuti doziranje levodope/benzerazida noć prije i započeti s Corbiltom sljedeće jutro.
The following adverse reactions, listed in Table 1, have been accumulated both from a pooled data of eleven double-blind clinical trials consisting of 3230 patients (1810 treated with Corbilta or entacapone combined with levodopa/DDC inhibitor, and 1420 treated with placebo combined with levodopa/DDC inhibitor or cabergoline combined with levodopa/ DDC inhibitor), and from the postmarketing data since the introduction of entacapone into the market for the combination use of entacapone with levodopa/DDC inhibitor. 
Sljedeće nuspojave, navedene u Tablici 1, prikupljene su i iz objedinjenih podataka jedanaest dvostruko slijepih kliničkih ispitivanja u kojima su bila uključena 3230 bolesnika (1810 liječenih Corbiltom ili entakaponom u kombinaciji s levodopom/DDC-inhibitorom, i 1420 liječenih placebom u kombinaciji s levodopom/DDC-inhibitorom ili kabergolinom u kombinaciji s levodopom/DDCinhibitorom) i iz podataka dobivenih nakon stavljanja entakapona na tržište za njegovu kombiniranu primjenu s levodopom/DDC-inhibitorom.
No particular studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal insufficiency, therefore Corbilta therapy should be administered cautiously to patients in severe renal impairment including those receiving dialysis therapy (see section 5.2). 
Nisu objavljena posebna ispitivanja farmakokinetike levodope i karbidope kod bolesnika s bubrežnom insuficijencijom, pa se stoga terapija Corbiltom mora oprezno primjenjivati kod bolesnika s teškim bubrežnim oštećenjem, uključujući bolesnike na dijalizi (vidjeti dio 5.2).
- Corbilta therapy should be administered cautiously to patients with ischemic heart disease, severe cardiovascular or pulmonary disease, bronchial asthma, renal or endocrine disease, history of peptic ulcer disease or history of convulsions. 
- Liječenje Corbiltom treba provoditi uz oprez u bolesnika s ishemijskom bolešću srca, teškom kardiovaskularnom ili plućnom bolešću, bronhijalnom astmom, bubrežnom ili endokrinom bolešću, kao i u bolesnika s peptičkim ulkusom ili konvulzijama u anamnezi.
How to take Corbilta 
Kako uzimati Corbiltu
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Corbilta. 
Bolesnici i skrbnici trebaju znati da se simptomi u ponašanju kod poremećaja kontrole impulsa uključujući patološko kockanje, pojačani libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, prejedanje i kompulzivno jedenje mogu javiti u bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim lijekovima koji sadrže levodopu, uključujući Corbiltu.
The possibility that the patient has taken other active substances in addition to Corbilta should be taken into consideration. 
Mora se uzeti u obzir mogućnost da je bolesnik uz Corbiltu uzeo i druge djelatne tvari.
How to transfer patients not currently treated with entacapone to Corbilta 
Kako na Corbiltu prebaciti bolesnike koji trenutno nisu liječeni entakaponom
Depression, hallucination, confusional state*, abnormal dreams*, anxiety, insomnia 
Depresija, halucinacija, konfuzno stanje*, poremećeni snovi*, anksioznost, nesanica Manje često: Psihoza, agitacija*
MAO-B inhibitors, or non-selective MAO-inhibitors) - have ever had neuroleptic malignant syndrome (NMS - this is a rare reaction to medicines used to treat severe mental disorders) - have ever had non-traumatic rhabdomyolysis (a rare muscle disorder) - have a severe liver disease. 
inhibitora, ili neselektivne MAO-inhibitore), - ako ste ikada imali neuroleptički maligni sindrom (NMS - to je rijetka reakcija na lijekove koji se koriste za liječenje teških duševnih poremećaja), - ako ste bilo kada imali netraumatsku rabdomiolizu (rijetki mišićni poremećaj), - ako imate tešku bolest jetre.
If you suddenly stop taking Corbilta and other antiparkinsonian medicines it may result in unwanted side effects. 
Naglo ukidanje Corbilte i drugih antiparkinsonika može rezultirati neželjenim nuspojavama.
Teл. 
Tel.
When less levodopa is required, the total daily dose of Corbilta should be reduced either by decreasing the frequency of administration by extending the time between doses, or by decreasing the strength of Corbilta at an administration. 
Kada je potrebno manje levodope, ukupna dnevna doza Corbilte mora se smanjiti ili smanjenjem učestalosti primjene povećanjem vremenskog razmaka između doza ili primjenom manje jačine Corbilte.
Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Corbilta (see section 
Poremećaji kontrole impulsa: Patološko kockanje, pojačani libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, prejedanje i kompulzivno jedenje mogu se javiti u bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim lijekovima koji sadrže levodopu, uključujući Corbiltu (vidjeti dio 4.4).
For example, a patient taking one tablet of 50 mg/12.5 mg of levodopa/carbidopa with one tablet of entacapone 200 mg four times daily can take one 50 mg/12.5 mg/200 mg Corbilta tablet four times daily in place of their usual levodopa/carbidopa and entacapone doses. 
Na primjer, bolesnik koji uzima jednu tabletu od 50 mg/12,5 mg levodope/karbidope s jednom tabletom entakapona 200 mg četiri puta dnevno može uzeti jednu Corbilta 50 mg/12,5 mg/200 mg tabletu četiri puta dnevno umjesto svojih uobičajenih doza levodope/karbidope i entakapona.
Corbilta is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment. 
Corbilta je indicirana za liječenje odraslih bolesnika s Parkinsonovom bolešću, kao i za liječenje motoričkih fluktuacija na kraju intervala doziranja koje nisu stabilizirane primjenom levodope/inhibitora dopa dekarboksilaze (DDC).
Patients should be instructed to take only one Corbilta tablet per dose administration. 
Bolesnike se mora upozoriti da prilikom svake primjene lijeka uzmu samo jednu tabletu Corbilte.
Corbilta comes in six different pack sizes (10, 30, 100, 130, 175 or 250 tablets). 
Corbilta dolazi u šest različitih veličina pakiranja (10, 30, 100, 130, 175 ili 250 tableta).
The effects of Corbilta may be weakened by certain medicines. 
Neki lijekovi mogu oslabiti učinke Corbilte.
If you during the treatment with Corbilta experience the following symptoms, contact your doctor immediately: - Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. 
Ako tijekom liječenja Corbiltom imate sljedeće simptome, odmah se javite svom liječniku: - Vaši su mišići postali jako ukočeni ili se snažno trzaju, pojavilo se nevoljno drhtanje, uznemirenost, smetenost, vrućica, ubrzani puls ili izrazite promjene krvnog tlaka.
Usually Corbilta is to be used in patients who are currently treated with corresponding doses of standard release levodopa/DDC inhibitor and entacapone. 
Corbiltu obično treba koristiti u bolesnika koji se već liječe odgovarajućim dozama levodope/DDCinhibitora sa standardnim oslobađanjem i entakapona.
No particular studies on the pharmacokinetics of carbidopa and levodopa in patients with hepatic impairment are reported, however, it is advised that Corbilta should be administered cautiously to patients with mild or moderate hepatic impairment. 
Nisu objavljena posebna ispitivanja farmakokinetike karbidope i levodope kod bolesnika s oštećenjem jetre, međutim, savjetuje se oprezna primjena Corbilte kod bolesnika s blagim ili umjerenim oštećenjem jetre.
Consult your doctor if during the treatment with Corbilta you: - notice that your muscles get very rigid or jerk violently, or if you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. 
Savjetujte se sa svojim liječnikom ako tijekom liječenja Corbiltom: - primijetite da Vam mišići postaju jako ukočeni ili se snažno trzaju, ako se pojavi drhtanje, uznemirenost, smetenost, vrućica, ubrzani puls ili izrazite promjene krvnoga tlaka.
You should not breast-feed during treatment with Corbilta. 
Tijekom liječenja Corbiltom ne smijete dojiti.
Breast-feeding Levodopa is excreted in human breast milk. 
Levodopa se izlučuje u majčino mlijeko u ljudi.
- Coadministration of Corbilta with non-selective monoamine oxidase (MAO-A and MAO-B) 
- Istodobna primjena Corbilte s neselektivnim inhibitorima monoaminooksidaze (MAO-A i
Talk to your doctor or pharmacist before taking Corbilta if you have or have ever had: - a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels - asthma or any other disease of the lungs - a liver problem, because your dose may need to be adjusted - kidney or hormone-related diseases 
Obratite se svom liječniku ili ljekarniku prije nego uzmete Corbilta ako imate ili ste ikada imali: - srčani udar ili bilo koju drugu bolest srca uključujući srčane aritmije, ili bolest krvnih žila - astmu ili bilo koju drugu bolest pluća, - probleme s jetrom, jer tada Vašu dozu možda treba prilagoditi, - bolesti povezane s bubrezima ili hormonima,
When decarboxylation of levodopa is reduced with the co-administration of a DDC inhibitor, a lower dose of levodopa can be used and the incidence of adverse reactionssuch as nausea is reduced. 
Kada se istodobnom primjenom DDCinhibitora smanji dekarboksilacija levodope, može se koristiti niža doza levodope, čime se smanjuje učestalost nuspojava kao što je mučnina.
Hepatic impairment: It is advised that Corbilta should be administered cautiously to patients with mild to moderate hepatic impairment. 
Oštećenje jetre: savjetuje se oprezna primjena Corbilte kod bolesnika s blagim do umjerenim oštećenjem jetre.
- If you are taking Corbilta 200 mg/50 mg/200 mg, do not take more than 7 tablets of this strength per day. 
- Ako uzimate Corbilta 200 mg/50 mg/200 mg tablete, nemojte uzeti više od 7 tableta dnevno.
- If you are taking Corbilta 175 mg/43.75 mg/200 mg tablets, do not take more than 8 tablets of this strength per day. 
- Ako uzimate Corbilta 175 mg/43,75 mg/200 mg tablete, nemojte uzeti više od 8 tableta dnevno.
As part of this PSUSA procedure, update of the levodopa/carbidopa/entacapone SmPCs with identical changes regarding dopamine dysregulation syndrome as agreed previously by the CMDh in the PSUSA process for levodopa/carbidopa containing products is considered warranted. 
Smatra se opravdanim da se u sklopu ovog PSUSA postupka ažuriraju sažeci opisa svojstava lijeka za levodopu/karbidopu/entakapon s identičnim promjenama vezano uz sindrom poremećene regulacije dopamina, kako je dogovoreno s CMDh-om u prethodnom PSUSA postupku za lijekove koji sadrže levodopu/karbidopu..
However, a longer dosing interval of Corbilta may be considered for patients who are receiving dialysis therapy (see section 4.2). 
Međutim, treba razmotriti dulji interval doziranja Corbilte u bolesnika koji su na dijalizi (vidjeti dio
How to store Corbilta 
Kako čuvati Corbiltu
- If you are taking Corbilta 50 mg/12.5 mg/200 mg, 75 mg/18.75 mg/200 mg, 
- Ako uzimate Corbilta 50 mg/12,5 mg/200 mg, 75 mg/18,75 mg/200 mg, 100 mg/25 mg/200 mg,
Ten tablets of Corbilta 150 mg/37.5 mg/200 mg equals 375 mg of carbidopa a day. 
Deset tableta Corbilte 150 mg/37,5 mg/200 mg odgovara 375 mg karbidope dnevno.
While the experience with total daily dose greater than 200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2,000 mg and therefore the maximum dose is 10 tablets per day for the Corbilta strengths of 50 mg/12.5 mg/200 mg, 75 mg/18.75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg and 150 mg/37.5 mg/200 mg. 
Kako je iskustvo s ukupnom dnevnom dozom većom od 200 mg karbidope ograničeno, a maksimalna preporučena dnevna doza entakapona je 2000 mg, stoga maksimalna doza Corbilte iznosi 10 tableta na dan za jačine od 50 mg/12,5 mg/200 mg, 75 mg/18,75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31,25 mg/200 mg i 150 mg/37,5 mg/200 mg.
Do not take Corbilta if you: 
Nemojte uzimati Corbiltu
Corbilta 50 mg/12.5 mg/200 mg film-coated tablets Corbilta 75 mg/18.75 mg/200 mg film-coated tablets Corbilta 100 mg/25 mg/200 mg film-coated tablets Corbilta 125 mg/31.25 mg/200 mg film-coated tablets Corbilta 150 mg/37.5 mg/200 mg film-coated tablets Corbilta 175 mg/43.75 mg/200 mg film-coated tablets Corbilta 200 mg/50 mg/200 mg film-coated tablets 
Corbilta 50 mg/12,5 mg/200 mg filmom obložene tablete Corbilta 75 mg/18,75 mg/200 mg filmom obložene tablete Corbilta 100 mg/25 mg/200 mg filmom obložene tablete Corbilta 125 mg/31,25 mg/200 mg filmom obložene tablete Corbilta 150 mg/37,5 mg/200 mg filmom obložene tablete Corbilta 175 mg/43,75 mg/200 mg filmom obložene tablete Corbilta 200 mg/50 mg/200 mg filmom obložene tablete
According to this daily carbidopa dose, the maximum recommended daily dose of Corbilta175 mg/43.75 mg/200 mg is 8 tablets per day and Corbilta 200 mg/50 mg/200 mg dose is 7 tablets per day. 
najviša preporučena dnevna doza Corbilte 175 mg/43,75 mg/200 mg je 8 tableta na dan, a Corbilte 200 mg/50 mg/200 mg je 7 tableta na dan.
b. When initiating Corbilta therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Corbilta tablets (50 mg/12.5 mg/200 mg or 75 mg/18.75 mg/200 mg or 100 mg/25 mg/200 mg or 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg), Corbilta dosing should be carefully titrated for optimal clinical response. 
Kada se terapija Corbiltom uvodi bolesnicima koji su trenutno liječeni entakaponom i levodopom/karbidopom u dozama koje ne odgovaraju Corbilta tabletama (50 mg/12,5 mg/200 mg ili 75 mg/18,75 mg/200 mg ili 100 mg/25 mg/200 mg ili 125 mg/31,25 mg/200 mg ili 150 mg/37,5 mg/200 mg ili 175 mg/43,75 mg/200 mg ili 200 mg/50 mg/200 mg), doziranje Corbilte mora biti pažljivo titrirano radi optimalnog kliničkog odgovora.
corbilta 75/18.75/200 mg [carton only] 
corbilta 75/18,75/200 mg [samo kutija]
corbilta 125/31.25/200 mg [carton only] 
corbilta 125/31,25/200 mg [samo kutija]
organizačná zložka Tel: +421 2 48 200 600 
Slovenská republika Sandoz d.d. organizačná zložka Tel: +421 2 48 200 600
corbilta 175/43.75/200 mg [carton only] 
corbilta 175/43,75/200 mg [samo kutija]
Corbilta contains sucrose 
Corbilta sadrži saharozu
corbilta 150/37.5/200 mg [carton only] 
corbilta 150/37,5/200 mg [samo kutija]
- Periodic evaluation of hepatic, haematopoietic, cardiovascular and renal function is recommended during extended therapy with Corbilta. 
- Tijekom produžene terapije Corbiltom preporučuje se povremeno pratiti jetrene, hematopoetske, kardiovaskularne i bubrežne funkcije.
corbilta 50/12.5/200 mg [carton only] 
corbilta 50/12,5/200 mg [samo kutija]
corbilta 100/25/200 mg [carton only] 
corbilta 100/25/200 mg [samo kutija]
corbilta 200/50/200 mg [carton only] 
corbilta 200/50/200 mg [samo kutija]
Tel: +386 1 580 21 11 
Lek Pharmaceuticals d.d. Tel: +386 1 580 21 11